Risperdal Consta 25 mg powder and solvent for prolonged-release suspension for intramuscular injection

Spain
Brand name Risperdal Consta 25 mg powder and solvent for prolonged-release suspension for intramuscular injection
Form powder and solvent for preparation of prolonged-release injectable suspension
Active substance / Dosage
RISPERIDONE · 25 mg
Prescription type Prescription Only Medicine
Registration number 65213
Risperdal Consta 25 mg powder and solvent for prolonged-release suspension for intramuscular injection powder and solvent for preparation of prolonged-release injectable suspension

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Risperdal Consta 25 mg powder and solvent for prolonged-release suspension for injection

risperidone

Read the entire leaflet carefully before you start using this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it could harm them.
  • If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

  1. What Risperdal Consta is and what it is used for
  2. What you need to know before using Risperdal Consta
  3. How to use Risperdal Consta
  4. Possible side effects
  5. How to store Risperdal Consta
  6. Contents of the pack and other information

1. What Risperdal Consta is and what it is used for

Risperdal Consta belongs to a group of medicines called "antipsychotics".

Risperdal Consta is used for the maintenance treatment of schizophrenia, which is characterized by seeing, hearing, or feeling things that are not present, believing something that is not true, or unusually feeling distrust or confusion.

Risperdal Consta is intended for patients who are currently being treated with oral antipsychotics (e.g., tablets, capsules).

Risperdal Consta may help reduce the symptoms of your illness and help prevent them from returning.

2. What you need to know before using Risperdal Consta

Do not use Risperdal Consta

  • If you are allergic to risperidone or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

  • If you have never taken Risperdal in any form, you must start with oral Risperdal before beginning treatment with Risperdal Consta.

Talk to your doctor or pharmacist before using Risperdal Consta if:

  • You have a heart condition, for example an irregular heartbeat, or if you are prone to low blood pressure, or if you are taking medicines for blood pressure. Risperdal Consta may lower blood pressure. Your dose may need to be adjusted.
  • You know you have risk factors for stroke, such as high blood pressure (hypertension), cardiovascular disorders, or cerebral circulation disorders.
  • You have ever experienced involuntary movements of the tongue, mouth, or face.
  • You have ever had symptoms including fever, muscle stiffness, sweating, or decreased level of consciousness (also known as Neuroleptic Malignant Syndrome).
  • You have Parkinson's disease or dementia.
  • You have previously had low levels of white blood cells (which may or may not have been caused by other medications).
  • You are diabetic.
  • You have epilepsy.
  • You are male and have ever had a prolonged or painful erection.
  • You have difficulty regulating body temperature or feel excessive heat.
  • You have kidney problems.
  • You have liver problems.
  • You have abnormally high levels of the hormone called prolactin in your blood, or if you have a tumor that may be prolactin-dependent.
  • You or someone in your family has a history of blood clots, as medicines like this have been associated with blood clot formation.

If you are unsure whether any of the above applies to you, speak with your doctor or pharmacist before using Risperdal or Risperdal Consta.

Rarely, patients treated with Risperdal Consta have been observed to have a dangerously low number of a type of white blood cell essential for fighting infections. Your doctor may monitor your white blood cell count.

Allergic reactions may rarely occur after receiving injections of Risperdal Consta, even if you have previously tolerated oral risperidone. Seek immediate medical attention if you experience hives, throat swelling, itching, or breathing difficulties, as these may be signs of a serious allergic reaction.

Risperdal Consta may cause weight gain. Significant weight gain may negatively affect your health. Your doctor will regularly monitor your weight.

Since diabetes mellitus has been observed or pre-existing diabetes worsened in patients taking Risperdal, your doctor should check for signs of elevated blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be monitored regularly.

Risperdal Consta frequently increases levels of a hormone called "prolactin." This may cause adverse effects such as menstrual disorders or fertility problems in women, or breast enlargement in men (see Possible side effects). If these adverse effects occur, evaluation of blood prolactin levels is recommended.

During cataract surgery (clouding of the lens), the pupil (the black circle in the center of the eye) may not dilate as needed. In addition, the iris (the colored part of the eye) may become floppy during surgery, which could cause eye damage. If you are considering eye surgery, make sure to inform your ophthalmologist that you are taking this medicine.

Elderly patients with dementia

Risperdal Consta is not used in elderly patients with dementia.

If you or your caregiver notice a sudden change in your mental state or sudden onset of weakness or numbness in the face, arms, or legs—especially on one side—or slurred speech, even if brief, seek immediate medical treatment. These may be signs of a stroke.

Patients with kidney or liver problems

Although oral risperidone has been studied, Risperdal Consta has not been studied in patients with kidney or liver problems. Risperdal Consta should be used with caution in this patient group.

Using Risperdal Consta with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

It is especially important that you talk to your doctor or pharmacist if you are taking any of the following:

  • Medicines that act on the brain used to calm you (benzodiazepines) or certain pain medicines (opioids), allergy medicines (some antihistamines), as risperidone may increase the sedative effect of these.
  • Medicines that can alter the electrical activity of your heart, such as those used for malaria, heart rhythm disorders, allergies (antihistamines), certain antidepressants, or other medicines for mental disorders.
  • Medicines that may cause a decrease in heart rate.
  • Medicines that may cause low potassium levels in the blood (such as certain diuretics).
  • Medicines for Parkinson's disease (such as levodopa).
  • Medicines that increase central nervous system activity (psychostimulants, such as methylphenidate).
  • Medicines for high blood pressure. Risperdal Consta may lower blood pressure.
  • Diuretics used for heart problems or to treat swelling in certain body parts due to fluid retention (such as furosemide or chlorothiazide). Risperdal Consta, taken alone or with furosemide, may increase the risk of stroke or death in elderly patients with dementia.

The following medicines may reduce the effect of risperidone:

  • Rifampicin (a medicine used to treat certain infections).
  • Carbamazepine, phenytoin (medicines used to treat epilepsy).
  • Phenobarbital.

If you start or stop taking these medicines, you may need a different dose of risperidone.

The following medicines may increase the effect of risperidone:

  • Quinidine (a medicine used to treat certain types of heart problems).
  • Antidepressants such as paroxetine, fluoxetine, tricyclic antidepressants.
  • Medicines known as beta-blockers (used to treat high blood pressure).
  • Phenothiazines (such as medicines used to treat psychosis or to calm).
  • Cimetidine, ranitidine (medicines used to treat stomach acidity).
  • Itraconazole and ketoconazole (medicines used to treat fungal infections).
  • Certain medicines used to treat HIV/AIDS, such as ritonavir.
  • Verapamil, a medicine used to treat high blood pressure and/or abnormal heart rhythm.
  • Sertraline and fluvoxamine, medicines used to treat depression and other psychiatric disorders.

If you start or stop taking these medicines, you may need a different dose of risperidone.

If you are unsure whether any of the above applies to you, speak with your doctor or pharmacist before using Risperdal Consta.

Use of Risperdal Consta with food, drinks, and alcohol

You should avoid consuming alcohol while using Risperdal Consta.

Pregnancy, breastfeeding, and fertility

  • If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. Your doctor will decide whether you can use it.
  • The following symptoms may occur in newborn babies of mothers who have been treated with Risperdal Consta during the last trimester of pregnancy (last three months of pregnancy): tremors, muscle stiffness and/or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If your baby develops any of these symptoms, contact your doctor.
  • Risperdal Consta may increase levels of a hormone called "prolactin," which could affect your fertility (see Possible side effects).

Driving and using machines

Dizziness, fatigue, and vision problems have been reported during treatment with Risperdal Consta. Do not drive or operate tools or machinery without first consulting your doctor.

Risperdal Consta contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per dose; this is essentially "sodium-free."

3. How to use Risperdal Consta

Follow exactly the administration instructions for this medicine as given by your doctor. If in doubt, consult your doctor or pharmacist again.

Risperdal Consta is administered by intramuscular injection into the arm or buttock every two weeks by a healthcare professional. Injections should alternate between the left and right sides and must not be given intravenously.

Recommended dosage is as follows:

Adults

Initial dose

If your daily oral risperidone dose (e.g., tablets) was 4 milligrams or less during the previous two weeks, your starting dose should be 25 milligrams of Risperdal Consta.

If your daily oral risperidone dose (e.g., tablets) was more than 4 milligrams during the previous two weeks, you may be given the 37.5 milligram dose of Risperdal Consta as the starting dose.

If you are currently being treated with another oral antipsychotic other than risperidone, your starting dose of Risperdal Consta will depend on your current treatment. Your doctor will choose either Risperdal Consta 25 mg or 37.5 mg.

Your doctor will decide whether this Risperdal Consta dose is appropriate for you.

Maintenance dose

  • The usual dose is a 25 milligram injection every two weeks.
  • A higher dose of 37.5 or 50 mg may be required. Your doctor will decide which Risperdal Consta dose is most suitable for you.
  • Your doctor may prescribe oral Risperdal during the first three weeks after the first injection.

If you use more Risperdal Consta than you should

  • People who have used more Risperdal Consta than they should have experienced the following symptoms: drowsiness, fatigue, abnormal body movements, difficulty standing and walking, dizziness due to decreased blood pressure, and abnormal heartbeats. Cases of abnormalities in the heart's electrical conduction and seizures have been reported.
  • Contact your doctor, pharmacist, or call the Toxicology Information Service immediately at 91.562.04.20, indicating the medicine and amount taken.

It is recommended to carry the medicine packaging and package leaflet to the healthcare professional.

If you stop using Risperdal Consta

The effects of this medicine will be lost. You should not stop using this medicine unless instructed by your doctor, as your symptoms may return. Make sure to receive your injections every two weeks. If you cannot attend your appointments, contact your doctor immediately to schedule another appointment. If you have any further questions about using this medicine, ask your doctor or pharmacist.

Use in children and adolescents

Children and adolescents under 18 years of age must not be given Risperdal Consta.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them.

Immediately inform your doctor if you experience any of the following uncommon adverse effects (may affect up to 1 in 100 patients):

  • You have dementia and experience a sudden change in your mental state or sudden weakness or numbness of the face, arms, or legs, especially on one side, or you have difficulty speaking even for a short period. These may be signs of a stroke.
  • You develop tardive dyskinesia (involuntary spasms or twitching movements in the face, tongue, or other parts of the body). Inform your doctor immediately if you experience rhythmic, involuntary movements of the tongue, mouth, or face. Discontinuation of Risperdal Consta may be necessary.

Immediately inform your doctor if you experience any of the following rare adverse effects (may affect up to 1 in 1,000 patients):

  • You develop blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness of the leg), which may travel through the bloodstream to the lungs, causing chest pain and difficulty breathing. If you notice any of these symptoms, seek medical advice immediately.
  • You develop fever, muscle rigidity, sweating, or decreased level of consciousness (a condition known as "Neuroleptic Malignant Syndrome"). Immediate medical treatment may be required.
  • You are a man and experience a prolonged or painful erection. This is known as priapism. Immediate medical treatment may be needed.
  • You experience a severe allergic reaction characterized by fever, swelling of the mouth, face, lips, or tongue, difficulty breathing, itching, skin rash, or low blood pressure. Even if you previously tolerated oral risperidone, allergic reactions may rarely occur after receiving Risperdal Consta injections.

Other adverse effects that may occur include:

Very common adverse effects (may affect more than 1 in 10 people)

  • Symptoms of common cold
  • Difficulty falling or staying asleep
  • Depression, anxiety
  • Parkinsonism: This condition may include slow or impaired movement, muscle stiffness or tightness (causing jerky movements), and sometimes a sensation of "freezing" in movement that then restarts. Other signs of parkinsonism include slow shuffling gait, resting tremor, increased saliva and/or drooling, and reduced facial expression.
  • Headache.

Common adverse effects (may affect up to 1 in 10 people)

  • Pneumonia, chest infection (bronchitis), sinusitis
  • Urinary tract infection, feeling as if you have the flu, anemia
  • Increased levels of a hormone called "prolactin" detected in blood tests (which may or may not cause symptoms). Symptoms of elevated prolactin rarely occur and in men may include breast enlargement, difficulty achieving or maintaining erections, decreased sexual desire, or other sexual dysfunctions. In women, they may include breast discomfort, milk secretion from the breasts, loss of menstrual periods, or other menstrual cycle problems or fertility issues
  • Increased blood sugar, weight gain, increased appetite, weight loss, decreased appetite
  • Sleep disorder, irritability, decreased sexual desire, restlessness, feeling drowsy or less alert
  • Dystonia: A condition involving involuntary, slow, or sustained muscle contractions. Although any part of the body may be affected (leading to abnormal postures), dystonia often affects facial muscles, including abnormal eye, mouth, tongue, or jaw movements
  • Dizziness
  • Dyskinesia: A condition involving involuntary muscle movements, which may include repetitive, spasmodic, or twisting movements, or spasms
  • Tremor (shakiness)
  • Blurred vision
  • Rapid heartbeat
  • Low blood pressure, chest pain, high blood pressure
  • Shortness of breath, sore throat, cough, nasal congestion
  • Abdominal pain, abdominal discomfort, vomiting, nausea, stomach or intestinal infection, constipation, diarrhea, indigestion, dry mouth, toothache
  • Skin rash
  • Muscle spasms, bone or muscle pain, back pain, joint pain
  • Urinary incontinence (loss of bladder control)
  • Erectile dysfunction
  • Loss of menstrual periods
  • Milk secretion from the breasts
  • Swelling of the body, arms, or legs, fever, weakness, fatigue (tiredness)
  • Pain
  • Reaction at the injection site, including itching, pain, or swelling
  • Increased liver transaminases in blood, increased GGT (a liver enzyme called gamma-glutamyltransferase) in blood
  • Falls.

Uncommon adverse effects (may affect up to 1 in 100 people)

  • Respiratory tract infection, bladder infection, ear infection, eye infection, tonsillitis, fungal nail infection, skin infection, localized infection in a single area of skin or body part, viral infection, skin inflammation caused by mites, subcutaneous abscess

  • Decreased number of white blood cells, decreased platelets (blood cells that help stop bleeding), decreased red blood cells

  • Allergic reaction

  • Sugar in urine, diabetes, or worsening of diabetes

  • Loss of appetite leading to malnutrition and reduced body weight

  • Increased blood triglycerides (fat), increased blood cholesterol

  • Euphoria (mania), confusion, inability to achieve orgasm, nervousness, nightmares

  • Loss of consciousness, seizures (epileptic fits), fainting

  • Restlessness causing body movements, balance disorder, abnormal coordination, dizziness upon standing, attention disturbance, speech problems, loss or changes in taste, reduced skin sensitivity to pain or touch, tingling, prickling, or numbness of the skin

  • Eye infection or "red eye", dry eyes, increased tearing, eye redness

  • Sensation of spinning (vertigo), ringing in the ears, ear pain

  • Atrial fibrillation (abnormal heart rhythm), interruption of conduction between upper and lower heart chambers, abnormal electrical activity of the heart, QT interval prolongation on the electrocardiogram (ECG), slow heartbeat, abnormal electrical conduction of the heart (ECG), fluttering or pounding sensation in the chest (palpitations)

  • Decreased blood pressure upon standing (as a result, some people taking Risperdal Consta may feel weakness, dizziness, or loss of consciousness when standing up or sitting up suddenly)

  • Rapid, shallow breathing, respiratory congestion, gasping, nosebleeds

  • Fecal incontinence, difficulty swallowing, excessive gas or flatulence

  • Itching, hair loss, eczema, dry skin, skin redness, skin discoloration, acne, scaly or itchy scalp or skin

  • Increased CPK (creatine phosphokinase) in blood, an enzyme sometimes released during muscle breakdown

  • Joint stiffness, joint swelling, muscle weakness, neck pain

  • Frequent urination, inability to urinate, painful urination

  • Ejaculation disorder, delayed menstruation, loss of menstrual periods or other menstrual cycle problems (in women), breast development in men, sexual dysfunction, breast pain, breast discomfort, vaginal discharge

  • Swelling of the face, mouth, eyes, or lips

  • Chills, increased body temperature

  • Change in walking pattern

  • Thirst sensation, feeling unwell, chest discomfort, feeling "under the weather"

  • Skin hardening

  • Increased liver enzymes in blood

  • Pain due to the procedure.

Rare adverse effects (may affect up to 1 in 1,000 people)

  • Decreased number of a type of white blood cells that help fight infections
  • Inappropriate secretion of a hormone that controls urine volume
  • Low blood sugar
  • Excessive water intake
  • Sleepwalking
  • Sleep-related eating disorder
  • Lack of movement or response while awake (catatonia)
  • Absence of emotions
  • Decreased level of consciousness
  • Head agitation
  • Eye movement problems, eye rolling, light sensitivity
  • Eye problems during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) may occur if you are taking or have taken Risperdal Consta. If you need cataract surgery, make sure to inform your ophthalmologist if you are taking or have taken this medicine
  • Irregular heartbeat
  • Dangerously low number of a type of white blood cells needed to fight infections in the blood, increased eosinophils (a type of white blood cell) in blood
  • Breathing difficulty during sleep (sleep apnea)
  • Pneumonia caused by aspiration of food, lung congestion, crackling lung sounds, voice disorder, respiratory tract disorder
  • Pancreatitis, intestinal obstruction
  • Very hard stools
  • Drug-related skin rash
  • Hives (or "urticaria"), skin thickening, dandruff, skin disorder, skin lesion
  • Muscle fiber breakdown and muscle pain (rhabdomyolysis)
  • Postural abnormality
  • Breast enlargement, milk secretion from breasts
  • Decreased body temperature, malaise
  • Yellowing of the skin and eyes (jaundice)
  • Dangerously excessive water intake
  • Increased insulin (a hormone that controls blood sugar levels) in blood
  • Problems with blood vessels in the brain
  • No response to stimuli
  • Coma due to uncontrolled diabetes
  • Sudden loss of vision or blindness
  • Glaucoma (increased pressure in the eyeball), crusting at the edge of the eyelid
  • Flushing, tongue swelling
  • Cracked lips
  • Increased mammary glands
  • Decreased body temperature, coldness in arms and legs
  • Medication withdrawal symptoms.

Very rare adverse effects (may affect up to 1 in 10,000 people)

  • Life-threatening complications from uncontrolled diabetes
  • Severe allergic reaction with swelling, which may affect the throat and cause breathing difficulty
  • Lack of movement in intestinal muscles leading to obstruction.

Frequency not known: cannot be estimated from available data

  • Severe or life-threatening blistering rash with skin peeling that may start around the mouth, nose, eyes, genitals, and spread to other body areas (Stevens-Johnson Syndrome or toxic epidermal necrolysis).

The following adverse effect has been reported with the use of another medicine called paliperidone, which is very similar to risperidone; therefore, it is also expected to occur with Risperdal Consta: Rapid heartbeat upon standing.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Risperdal Consta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month indicated.

Store in a refrigerator (between 2°C and 8°C). If refrigeration is not available, the pack may be stored below 25°C for a maximum of 7 days prior to administration. Administer within 6 hours after reconstitution (if stored at 25°C or less).

Keep in the original packaging to protect from light.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the container and other information

Composition of Risperdal Consta

The active substance is risperidone.

Each Risperdal Consta powder and solvent for prolonged-release injection suspension contains 25 milligrams of risperidone.

The other components are:

Powder:

poly-(d,l-lactide-co-glycolide).

Solvent (solution):

Polysorbate 20, sodium carboxymethylcellulose, disodium hydrogen phosphate dihydrate, anhydrous citric acid, sodium chloride, sodium hydroxide, water for injection.

Appearance of Risperdal Consta and contents of the pack

  • One small vial containing the powder (this powder contains the active substance, risperidone). One pre-filled syringe containing 2 ml of clear, colourless liquid which is added to the powder to form a prolonged-release injection suspension.
  • One vial adapter for reconstitution
  • Two Terumo SurGuard® 3 needles for intramuscular injection (one 21G UTW safety needle, 1 inch (0.8 mm × 25 mm), with needle safety guard for administration into the deltoid muscle, and one 20G TW safety needle, 2 inches (0.9 mm × 51 mm), with needle safety guard for administration into the gluteal muscle).

Risperdal Consta is available in packs containing from 1 to 5 packs.

Some pack sizes may not be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Janssen-Cilag, S.A.

Paseo del Club Deportivo 1, Edificio 16

28223 Pozuelo de Alarcón (Madrid)

Spain

Manufacturer

Janssen Pharmaceutica, N.V.

Turnhoutseweg, 30

B-2340, Beerse

Belgium

This medicinal product has been authorised in the EEA Member States under the following names:

Austria: RISPERDAL CONSTA

Belgium: RISPERDAL CONSTA

Cyprus: RISPERDAL CONSTA

Czech Republic: RISPERDAL CONSTA

Denmark: RISPERDAL CONSTA

Estonia: RISPOLEPT CONSTA

Finland: RISPERDAL CONSTA

France: RISPERDAL CONSTA LP

Germany: RISPERDAL CONSTA 25mg, 37.5mg, 50mg

Greece: RISPERDAL CONSTA

Hungary: RISPERDAL CONSTA

Iceland: RISPERDAL CONSTA

Ireland: RISPERDAL CONSTA

Italy: RISPERDAL

Lithuania: RISPOLEPT CONSTA

Latvia: RISPOLEPT CONSTA

Liechtenstein: RISPERDAL CONSTA

Luxembourg: RISPERDAL CONSTA

Malta: RISPERDAL CONSTA

Netherlands: RISPERDAL CONSTA

Norway: RISPERDAL CONSTA

Poland: RISPOLEPT CONSTA

Portugal: RISPERDAL CONSTA

Romania: RISPOLEPT CONSTA

Slovakia: RISPERDAL CONSTA

Slovenia: RISPERDAL CONSTA

Spain: RISPERDAL CONSTA

Sweden: RISPERDAL CONSTA

United Kingdom: RISPERDAL CONSTA

This leaflet was last reviewed in: April 2021.

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es

IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS

Important information

RISPERDAL CONSTA requires careful attention at each step of the "Instructions for Use" to help ensure successful administration.

Use of supplied components

The components in the pack are specifically designed for use with RISPERDAL CONSTA. RISPERDAL CONSTA must be reconstituted only with the solvent supplied in the pack.

Do not substitute ANY of the pack components.

Do not store the suspension after reconstitution

Administer the dose as soon as possible after reconstitution to avoid sedimentation.

Appropriate dosing

The entire contents of the vial must be administered to ensure the correct dose of RISPERDAL CONSTA is delivered.

Black banner with white uppercase text: SINGLE-USE DEVICE

Do not reuse. Medical devices require materials with specific characteristics to function properly. These characteristics have been verified for single use only. Any attempt to reprocess the device for subsequent reuse may adversely affect the device's integrity or lead to impaired performance.

Pack components

Medical diagram showing components of a pre-filled syringe, vial adapter, vial with microspheres, and injection angles into the deltoid and gluteal muscles

Step 1

Assemble the components

Remove the dose container

Attach the vial adapter to the vial

Circular clock with the right half highlighted in yellow showing 30 minutes, above a white 3D rectangle on a gray background

Wait 30 minutes

Remove the dose container from the refrigerator and allow it to reach room temperature for at least 30 minutes before reconstitution.

Do not heat in any other way.

A hand holds a glass vial while a

Remove the vial cap

Remove the colored cap from the vial.

Clean the top of the grey stopper with an alcohol swab. Allow it to dry completely.

Do not remove the grey rubber stopper.

Two hands hold and position a circular medical device with a flat base and a central dome-shaped structure

Prepare the vial adapter

Hold the sterile blister pack as shown.

Peel off the paper backing.

Do not remove the vial adapter from the blister pack.

Do not touch the spike tip at any time, as this may cause contamination.

Two hands hold a glass vial while a black arrow indicates downward movement to press the cap onto the flat base

Attach the vial adapter to the vial

Place the vial on a hard surface and hold it by the base. Center the vial adapter over the grey rubber stopper. Press the vial adapter straight down firmly until it securely snaps into place on the vial.

Do not attach the vial adapter at an angle, as this may result in loss of solvent during transfer to the vial.

Black-and-white drawing showing a hand holding a vial with an error mark and the word 'Incorrect' at the top

Attach the pre-filled syringe to the vial adapter

A hand lifts a plastic cap upward toward the

Remove the sterile blister

Rounded rectangular box containing Spanish text warning to remove the

Keep the vial upright to prevent spillage.

Hold the base of the vial and pull off the sterile blister.

Do not shake.

Do not touch the exposed open luer (cone) on the vial adapter.

This may result in contamination.

Line drawing of a hand firmly gripping a small cylindrical medical device or injection penUse the correct gripping area

Hold the syringe by the white ring at the tip.

Do not hold the syringe by the glass during assembly.

Line drawing of a hand holding a pen-shaped medical device with an error symbol and the word 'Incorrect' at the top

Two hands holding and breaking apart a medical container with the word '¡ROMPER!' above the separated parts, indicated by motion lines

Remove the cap

Holding the white ring, break off the white cap.

Do not twist or cut the white cap.

Do not touch the tip of the syringe. This may result in contamination.

Technical drawing of a horizontal syringe with plunger and protective cap on a white background, with Spanish text below The broken cap can be discarded.

Hands holding a syringe to insert the

Attach the syringe to the vial adapter

Hold the vial adapter by the rim to keep it steady.

Hold the syringe by the white ring and insert the tip into the luer (cone) opening of the vial adapter.

Do not hold the syringe by the glass barrel.

This may cause the white ring to loosen or detach.

Connect the syringe to the vial adapter with a firm clockwise twisting motion until tight.

Do not over-tighten.

Over-tightening may cause the syringe tip to break.

Step 2

Reconstitute the microspheres

One hand holds a syringe and pushes it downward with a black arrow indicating aspiration of liquid from a small glass vial

Inject solvent

Inject the full amount of solvent from the syringe into the vial.

Warning box with exclamation symbol and Spanish text indicating the vial contents are under pressure and to press the clip of the

One hand holds a syringe moving it up and down with a timer indicating 10 seconds

Suspend the microspheres in the solvent

Continue pressing down on the plunger with your thumb and shake vigorously, as shown, for at least 10 seconds.

Inspect the suspension.

When properly mixed, the suspension will appear uniform, dense, and milky in color.

The microspheres will be visible in the liquid.

Proceed immediately to the next step to prevent sedimentation of the suspension.

One hand holds a syringe connected to a vial, with a black arrow indicating downward movement to push the plunger

Transfer the suspension into the syringe

Completely invert the vial.

Slowly pull down the plunger rod to draw all the contents of the vial into the syringe.

Technical drawing showing two hands rotating a medication vial to attach it to a syringe, following a black circular arrow

Remove the vial adapter

Hold the syringe by the white ring and unscrew it from the vial adapter.

Cut the vial label along the perforated line.

Apply the detached label to the syringe for identification.

Dispose of the vial and vial adapter properly (see section 5 of this leaflet).

Step 3

Attach the needle

Medical diagram showing the

Select the appropriate needle

Select the needle according to the injection site

(gluteal or deltoid).

Two hands open a medical device package by folding the paper flap outward

Attach the needle

Open the blister pack at the partially peeled area and use it to hold the base of the needle, as shown. Holding the white ring of the syringe, attach the syringe to the luer (cone) of the needle with a firm clockwise rotating motion until it is securely tightened.

Do not touch the opening of the luer (cone) of the needle. This may cause contamination.

Black-and-white drawing of a hand gripping an injection pen with two black arrows indicating vertical up-and-down movement

Resuspend the microspheres

Completely remove the blister pack.

Just before injection, shake the syringe vigorously again in case sedimentation has occurred.

Step 4

Inject the dose

Technical drawing showing two hands separating components of a medical device with black arrows indicating the opening motion

Remove the transparent needle cap

Move the needle safety device toward the syringe as shown.

Then, hold the white ring of the syringe and carefully remove the transparent needle cap. Do not twist the transparent needle cap, as this may dislodge the luer (cone) connection.

Two hands grip a syringe with a needle and a lever device, with a black arrow indicating movement toward the

Remove air bubbles

Hold the syringe upright and gently tap it to allow air bubbles to rise to the top. Slowly and carefully depress the plunger rod to expel the air.

Schematic drawing of a human torso viewed from the back with two black arrows indicating the shoulder and lower back areas

Inject

Immediately inject the entire contents of the syringe intramuscularly (IM) into the patient's gluteal or deltoid muscle.

The gluteal injection should be administered into the upper outer quadrant of the buttock. Do not administer intravenously.

Technical drawing showing the motion of a lever being lowered downward to touch a flat surface, with a detailed close-up

Protect the needle with the safety device

Using one hand, place the needle safety device at a 45-degree angle onto a hard, flat surface.

Press down firmly and quickly until the needle is fully enclosed within the safety device.

To prevent needlestick injury:

Do not use both hands.

Do not deliberately disengage or improperly manipulate the needle safety device.

Do not attempt to straighten the needle or engage the safety device if the needle is bent or damaged.

Line drawing of a hand disposing of a used needle into a biohazard waste container with a biohazard symbol

Dispose of needles properly

Ensure that the needle safety device is fully engaged.

Dispose of it in a sharps container. Also dispose of the unused needle provided in the dose packaging (see section 5 of this leaflet).